An observational study in Carcinoma, Non-Small-Cell Lung, sponsored by Janssen-Cilag Farmaceutica Ltda.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Janssen-Cilag Farmaceutica Ltda. (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson — 7 open to participants now, 18 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Johnson & Johnson.
Among the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, this one is one of 3 that started in 2026, is one of 7 observational ones, reaches primary completion later than 5 of the 17 other live ones, and was the 36th registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →7 of the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Canada, China and 3 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Canada, China and 2 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Austria, Belgium, Czechia and 5 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Belgium, Finland and 11 more countries
Ages 18+
Johnson & Johnson Enterprise Innovation Inc. · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 14 · Phase 3 4
First in 2012; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 160 across 1,150 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 70 across the 28 interventional studies, 105 across the 7 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen-Cilag Farmaceutica Ltda., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag Farmaceutica Ltda. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
8 of the studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07680907Janssen-Cilag Farmaceutica Ltda.A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm) | 2026-11-30 |
| NCT02609776Janssen Research & Development, LLCStudy of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer | 2026-12-31 |
| NCT05908734Janssen Research & Development, LLCA Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer | 2027-01-31 |
| NCT04077463Janssen Research & Development, LLCA Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer | 2027-02-12 |
| NCT06116786Johnson & Johnson Enterprise Innovation Inc.A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | 2027-04-14 |
Add all 8 to your calendar (.ics) → With an account.
Among the 36 studies in Carcinoma, Non-Small-Cell Lung by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to better understand people who have advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation. NSCLC is an advanced stage cancer of the lung, occurring due to mutations (changes) in the EGFR gene. The study will assess the participant demographic background (that is age, gender etc.), the treatments they receive, how well those treatments work, and their health outcomes.
Adult participants (aged greater than or equal to [>=] 18 years) with a histologically or cytologically confirmed diagnosis of NSCLC, unresectable stage IIIB/C or IV at diagnosis, and a documented EGFR mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC), unresectable stage IIIB/C or IV at diagnosis, and a documented EGFR mutation will be included in this cohort. The existing secondary data from electronic health records (EHR) of these participants from approximately five selected Portuguese healthcare sites will be processed. Each participant will be followed up from index date (date on which participant is included in study) up to 31 March 2026 or at censoring, No intervention will be provided as a part of this study.
Sociodemographic Characteristics: Age
Age in years of the participants will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Sex
Sex (male, female) of the participants will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Weight
Weight (in kilograms \[kg\]) of the participants will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Smoking Status
Participants smoking status that is current or former smoker will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG performance status of the participants will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Disease Histopathology
Number of participants based on disease histopathology will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Type of Mutation
Number of participants based on type of mutation will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Disease Stage
Number of participants based on the stage of disease will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Cancer Metastasis
Number of participants based on cancer metastasis will be reported.
Time frame: Baseline
EGFR Mutation Prevalence
Number of participants with EGFR mutations will be reported.
Time frame: Up to approximately 7 years 9 months
Percentage of Participants by Type of Mutation of EGFR
Percentage of participants by type of mutation of EGFR will be reported.
Time frame: Up to approximately 7 years 9 months
Frequency of EGFR Mutations
Frequency of EGFR mutations will be reported.
Time frame: Up to approximately 7 years 9 months
Number of Participants by Treatment Options
Participants with different treatment options such as targeted therapy, chemotherapy, immunotherapy, surgery, radiotherapy stratified by type of mutation will be reported.
Time frame: Up to approximately 7 years 9 months
Real-World Overall Survival (RW-OS)
RW-OS is defined as time elapsed between index date and date of death from any cause.
Time frame: Up to approximately 7 years 9 months
Real-World Progression-Free Survival (RW-PFS)
RW-PFS is defined as the time elapsed between the start of a new line of treatment to the date of documented disease progression or death from any cause, whichever occurs first.
Time frame: Up to approximately 7 years 9 months
RW-PFS from First Line of Treatment (RW-PFS 2)
RW-PFS 2 is defined as the time elapsed between the start of a first line of treatment to the date of documented second disease progression or death from any cause, whichever occurs first.
Time frame: Up to approximately 7 years 9 months
Real-World Time on Treatment (RW-TOT)
RW-TOT is defined as the time elapsed between the start date of a line of treatment to the date of treatment discontinuation for any reason.
Time frame: Up to approximately 7 years 9 months
Real-World Time to Next Treatment (RW-TTNT)
RW-TTNT is defined as the time elapsed between the start of a given line of treatment to the initiation of the subsequent line of systemic therapy.
Time frame: Up to approximately 7 years 9 months
Real-World Overall Response Rate (RW-ORR)
RW-ORR is defined as the percentage of participants whose cancer show partial response or complete response of all target lesions following a specific line of treatment.
Time frame: Up to approximately 7 years 9 months
Number of Appointments
Number of appointments related to NSCLC by line of treatment such as oncology, pulmonology, primary care, radio-oncology, thoracic surgery, nursing, psychology, nutrition, physiotherapy will be reported.
Time frame: Up to approximately 7 years 9 months
Number of Participants Receiving Complementary Diagnostic and Therapeutic Procedures
Number of participants receiving complementary diagnostic and therapeutic procedures and type of complementary diagnostic and therapeutic procedures received (for example, imaging, laboratory tests, biopsies, radiotherapy sessions, surgery, medication) will be reported.
Time frame: Up to approximately 7 years 9 months
Number Participants with Emergency Room Visits Related to NSCLC
Number of participants with emergency room visits related to NSCLC will be reported.
Time frame: Up to approximately 7 years 9 months
Percentage of Participants Hospitalized
Percentage of participants with at least one hospitalization will be reported.
Time frame: Up to approximately 7 years 9 months
Number of Hospitalizations
Total number of hospitalizations for the participants will be reported.
Time frame: Up to approximately 7 years 9 months
Median Length of Stay
Median length of stay in days per hospitalization will be reported.
Time frame: Up to approximately 7 years 9 months
Net Costing
The net cost of different treatment practices per participants will be reported.
Time frame: Up to approximately 7 years 9 months
No study locations are listed for this record.
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Data sharing details ↗ · innovativemedicine.jnj.com
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Nov 2026, 0 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →
Janssen-Cilag Farmaceutica Ltda. →